User profiles for "author:Gareth Hughes"
Gareth HughesCaizio Verified email at caizio.com Cited by 20599 |
Nanostructure-mediated drug delivery
GA Hughes - Nanomedicine: nanotechnology, biology and medicine, 2005 - Elsevier
Nanotechnology is expected to have an impact on all industries including semiconductors,
manufacturing, and biotechnology. Tools that provide the capability to characterize and …
manufacturing, and biotechnology. Tools that provide the capability to characterize and …
Clinical variation in foot and mouth disease: sheep and goats.
RP Kitching, GJ Hughes - Revue scientifique et technique …, 2002 - europepmc.org
Foot and mouth disease (FMD) in adult sheep and goats is frequently mild or unapparent,
but can cause high mortality in young animals. The recent outbreak of FMD in the United …
but can cause high mortality in young animals. The recent outbreak of FMD in the United …
[HTML][HTML] Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis
G Hughes, H Toellner, H Morris, C Leonard… - Journal of clinical …, 2016 - mdpi.com
Idiopathic Pulmonary Fibrosis (IPF) now has two licensed treatments available. Pirfenidone
was the first drug to be licensed and approved for use, followed by nintedanib. We set out …
was the first drug to be licensed and approved for use, followed by nintedanib. We set out …
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical
benefit in patients with advanced EGFR-mutant (EGFRm+) non–small cell lung cancer …
benefit in patients with advanced EGFR-mutant (EGFRm+) non–small cell lung cancer …
[BOOK][B] The study of plant disease epidemics
LV Madden, G Hughes, F Van Den Bosch - 2007 - repository.rothamsted.ac.uk
Plant disease epidemics continue to impact a world increasingly concerned with the quantity
and quality of food supply. This useful reference and textbook provides a detailed exposition …
and quality of food supply. This useful reference and textbook provides a detailed exposition …
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
SR Wedge, DJ Ogilvie, M Dukes, J Kendrew, R Chester… - Cancer research, 2002 - AACR
Abstract ZD6474 [N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)
methoxy] quinazolin-4-amine] is a potent, po active, low molecular weight inhibitor of kinase …
methoxy] quinazolin-4-amine] is a potent, po active, low molecular weight inhibitor of kinase …
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
The mammalian target of rapamycin (mTOR) kinase forms two multiprotein complexes,
mTORC1 and mTORC2, which regulate cell growth, cell survival, and autophagy. Allosteric …
mTORC1 and mTORC2, which regulate cell growth, cell survival, and autophagy. Allosteric …
[HTML][HTML] Overall survival with ribociclib plus endocrine therapy in breast cancer
SA Im, YS Lu, A Bardia, N Harbeck… - New England journal …, 2019 - Mass Medical Soc
Background An earlier analysis of this phase 3 trial showed that the addition of a cyclin-
dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater …
dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater …
Regional and cellular gene expression changes in human Huntington's disease brain
A Hodges, AD Strand, AK Aragaki… - Human molecular …, 2006 - academic.oup.com
Huntington's disease (HD) pathology is well understood at a histological level but a
comprehensive molecular analysis of the effect of the disease in the human brain has not …
comprehensive molecular analysis of the effect of the disease in the human brain has not …
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Background In MONALEESA-2, ribociclib plus letrozole showed improved progression-free
survival compared with letrozole alone as first-line treatment for postmenopausal patients …
survival compared with letrozole alone as first-line treatment for postmenopausal patients …